Quarterly report pursuant to Section 13 or 15(d)

Description of the Business and Financial Condition (Details)

v3.22.2.2
Description of the Business and Financial Condition (Details)
$ in Thousands
 1 Months Ended 9 Months Ended 12 Months Ended
Feb. 23, 2021
USD ($)
shares
Dec. 29, 2020
USD ($)
Jan. 31, 2020
USD ($)
investor
Sep. 30, 2022
USD ($)
company
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of pharmaceutical and biotech companies (more than) | company       50    
Cumulative deficit       $ 145,982   $ 133,932
Net cash used in operations       13,102 $ 9,145 12,700
Secured convertible notes       9,879   $ 9,838
Net proceeds from offering       $ 0 $ 46,785  
IPO            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Public offering (in shares) | shares 2,127,660          
Net proceeds from offering $ 46,800          
Security Purchase Agreement | 2020 Convertible Noteholders            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Debt instrument, number of investors | investor     2      
Secured convertible notes     $ 17,500      
Term of secured notes     5 years      
Security Purchase Agreement | 2020 Convertible Noteholders | One 2020 Convertible Noteholder            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Proceeds from debt, net of issuance costs     $ 16,800      
Security Purchase Agreement | 2020 Secured Notes | One 2020 Convertible Noteholder            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Additional rights, principal amount     $ 5,000      
Security Purchase Agreement | Second Closing Note | One 2020 Convertible Noteholder            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Increase in secured convertible notes   $ 7,500